This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies. Here, PCNA is linked to familial pancreatic carcinoma.